| Michael Robinson, DO | |
|
1950 Main St., Roanoke, AL 36274-2512 | |
| (334) 863-2311 | |
| (334) 863-5596 |
| Full Name | Michael Robinson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 33 Years |
| Location | 1950 Main St., Roanoke, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194748731 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | D0306 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Compassus-gadsden | Southside, AL | Hospice |
| Tanner Medical Center-east Alabama | Wedowee, AL | Hospital |
| Tanner Medical Center - Carrollton | Carrollton, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tanner Primary Care Of Roanoke Inc | 1153663091 | 4 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
| Entity Name | Tmc Woodland Family Healthcare, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467600916 PECOS PAC ID: 3173681566 Enrollment ID: O20081030000426 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
| Entity Name | Regional Health Management Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639466584 PECOS PAC ID: 9638340201 Enrollment ID: O20110913000235 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
| Entity Name | Tanner Primary Care Of Wedowee Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396002515 PECOS PAC ID: 8426211905 Enrollment ID: O20120521000201 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
| Entity Name | Tanner Primary Care Of Roanoke Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255899092 PECOS PAC ID: 1153663091 Enrollment ID: O20190425001408 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Robinson, DO 1950 Main St, Roanoke, AL 36274-2512 Ph: (334) 863-2311 | Michael Robinson, DO 1950 Main St., Roanoke, AL 36274-2512 Ph: (334) 863-2311 |
News Archive
Researchers studying proteins in heart cells have unexpectedly discovered that a common microscopy fluorescent protein carries reversible photobleaching properties. This phenomenon may lead to inaccurate or unreliable data.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Manufacturing small proteins known as peptides is usually very time-consuming, which has slowed development of new peptide drugs for diseases such as cancer, diabetes, and bacterial infections.
› Verified 6 days ago
Russell D Peterson, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 965 Us Hwy 431, Roanoke, AL 36274 Phone: 334-863-2141 Fax: 334-863-8733 | |
Dr. Mitchell Carey Shirah, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 59664 Highway 22, Roanoke, AL 36274 Phone: 334-863-8952 Fax: 334-863-2361 |